Allergy Conjunctivitis Market Report 2026

The allergy conjunctivitis market size has grown strongly in recent years. It will grow from $2.63 billion in 2025 to $2.78 billion in 2026 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to increasing prevalence of allergic conditions, limited awareness of advanced therapies, dominance of conventional antihistamines, regional disparities in healthcare access, reliance on hospital pharmacies.

The allergy conjunctivitis market size is expected to see strong growth in the next few years. It will grow to $3.51 billion in 2030 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to rising adoption of biologics and immunotherapies, growth of telemedicine and digital health platforms, expansion of e-commerce in pharmaceuticals, increased government initiatives for eye care, innovation in patient-specific drug delivery. Major trends in the forecast period include rising prevalence of seasonal allergies, increasing demand for non-steroidal treatments, growth of online pharmacy channels, awareness of eye health and preventive care, expansion of pediatric and geriatric allergy care.

The prevalence of eye disorders is anticipated to drive the growth of the allergic conjunctivitis market. An eye disorder refers to any condition or abnormality that impacts the structure or function of the eyes, resulting in impaired vision or other eye-related symptoms. Allergic conjunctivitis represents an important segment within the range of eye disorders, particularly when the condition is caused by allergic responses. This type of conjunctivitis is marked by inflammation of the conjunctiva, the thin membrane covering the surface of the eye, and is commonly triggered by exposure to allergens such as pollen, dust, or pet dander. The increasing presence of environmental pollutants and chemicals has contributed to a rise in allergic conjunctivitis cases. For example, in August 2023, the World Health Organization, a Switzerland-based specialized agency of the United Nations, published an article stating that globally, at least 2.2 billion people experience near or distance vision impairment, and among these, 1 billion individuals have conditions causing distance vision impairment or blindness, including cataracts (94 million), refractive error (88.4 million), age-related macular degeneration (8 million), glaucoma (7.7 million), and diabetic retinopathy (3.9 million). Therefore, the growing prevalence of eye disorders is driving the allergic conjunctivitis market.

Major companies are active in the allergic conjunctivitis market and are concentrating on technological advancements such as eyelid-applied cream formulations to improve drug delivery, enhance patient compliance, and reduce dosing frequency. An eyelid-applied cream formulation is administered to the eyelids rather than directly into the eyes, enabling sustained release of antihistamines while minimizing irritation and improving adherence compared to conventional eye drops. For example, in May 2024, Santen Pharmaceutical, a Japan-based ophthalmology company, launched Alesion Eyelid Cream 0.5% for patients with allergic conjunctivitis. The product delivers epinastine hydrochloride through the eyelids, significantly reducing itching and redness, allows once-daily application, and demonstrates a favorable safety profile for long-term use.

In July 2023, Harrow Health, a US-based company specializing in the ophthalmic healthcare market, acquired the branded ophthalmic portfolio of Santen Holdings U.S. Inc. This acquisition allows Harrow to further its objective of becoming a leading company among the top tier of U.S. ophthalmic pharmaceutical firms and positions its branded portfolio as one of the most comprehensive in the U.S. market. Santen Holdings U.S. Inc. is a US-based provider of ophthalmology products and human eye health solutions.

Major companies operating in the allergy conjunctivitis market are Allergan PLC, AbbVie Inc., Ajanta Pharma Limited, Akron Operating Company LLC, Alcon Inc., Alembic Pharmaceuticals Ltd., Atopix Therapeutics Ltd., Auven Therapeutics Management LLLP, Bausch & Lomb, Cipla Ltd., Grevis Pharmaceutical Private Limited, Indoco Remedies Ltd., Jabs Biotech Pvt. Ltd., JAWA Pharmaceuticals Pvt. Ltd., Novartis AG, Ocular Therapeutix Inc., Santen Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., Laboratoires Thea SAS, Aciex Therapeutics Inc., Bausch Health Companies Inc., C.H. Boehringer Sohn AG & Co. KG, Eyevance Pharmaceuticals LLC, Johnson & Johnson Services Inc., Mylan N.V., Nicox S.A., Omeros Corporation, Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., Regeneron Pharmaceuticals Inc., Shire PLC, Teva Pharmaceutical Industries Ltd., Zydus Cadila.

North America was the largest region in the allergy conjunctivitis market share in 2025. The regions covered in the allergy conjunctivitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the allergy conjunctivitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the allergy conjunctivitis market by increasing the cost of imported drugs, raw materials, and specialized delivery devices, particularly affecting corticosteroids and combination therapies segments. Asia-Pacific and European import-reliant regions are most impacted, leading companies to diversify sourcing and localize manufacturing. While tariffs may raise prices temporarily, they also encourage local production innovation and the development of cost-effective therapies, providing potential long-term benefits to the market.

The allergy conjunctivitis market research report is one of a series of new reports that provides allergy conjunctivitis market statistics, including allergy conjunctivitis industry global market size, regional shares, competitors with a allergy conjunctivitis market share, detailed allergy conjunctivitis market segments, market trends and opportunities, and any further data you may need to thrive in the allergy conjunctivitis industry. This allergy conjunctivitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Allergic conjunctivitis is inflammation of the conjunctiva, the lining of the eye, caused by an allergic reaction to substances such as pollen or mold spores. The conjunctiva is the membrane or tissue that covers the inner surface of the eyelids and the white part of the eyeball. Symptoms of allergic conjunctivitis include red, itchy, and watery eyes.

The primary drug classes used for allergic conjunctivitis include antihistamines and mast cell stabilizers, corticosteroids, and others. Antihistamines and mast cell stabilizers are prescription or over-the-counter medications that block the physiological effects of histamines. The condition ranges from mild to severe, and treatments for conjunctivitis are distributed through hospital pharmacies, drug stores and retail pharmacies, as well as online pharmacies.

The allergy conjunctivitis market consists of sales of therapeutics that are used to treat inflammation of eyes caused due to allergens. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.